SEC Form CERT filed by Palatin Technologies Inc.
$PTN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | $60.00 | Buy | Laidlaw |
| 12/3/2025 | $50.00 | Buy | Alliance Global Partners |
| 11/24/2021 | $2.00 → $5.00 | Buy | HC Wainwright & Co. |
Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00
Alliance Global Partners initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $50.00
HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndromeOnce-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve t
Advancing differentiated MC4R-based obesity programs into clinical developmentMelanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndromeOral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)
CERT - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
8-A12B - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
25 - PALATIN TECHNOLOGIES INC (0000911216) (Filer)
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndromeOnce-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve t
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -
CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q
SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)
SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)